Human papillomavirus prevalence to age 60 years among Australian women prevaccination

Sexual Health

Volumn 12, Issue 4, 2015, Pages 353-359

  Brotherton, Julia M L ^a,b   Condon, John R ^c   Mcintyre, Peter B ^d   Tabrizi, Sepehr N ^b,e,f   Malloy, Michael ^a,b   Garland, Suzanne M ^b,e,f  

^a National HPV Vaccination Program Register   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e ROYAL WOMEN'S HOSPITAL   (Australia)

^f ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ADULT; ARTICLE; AUSTRALIAN; CLIMACTERIUM; EPIDEMIOLOGICAL MONITORING; FEMALE; GENOTYPE; GYNECOLOGICAL EXAMINATION; HIGH RISK POPULATION; HORMONAL CONTRACEPTION; HUMAN; HUMAN PAPILLOMAVIRUS PREVALENCE; HUMAN PAPILLOMAVIRUS TYPE 16; MIDDLE AGED; NONHUMAN; NORMAL HUMAN; PAPANICOLAOU TEST; PREVALENCE; SEXUAL BEHAVIOR; SEXUAL INTERCOURSE; SEXUALITY; UTERINE CERVIX; VACCINATION; VIRUS REACTIVATION; WART VIRUS;

EID: 84938679047     PISSN: 14485028     EISSN: 14498987     Source Type: Journal    
DOI: 10.1071/SH15035     Document Type: Article

References (21)

1. Bosch FX, Tsu V, Vorsters A, Van Damme P, Kane MA. Reframing cervical cancer prevention. Expanding the field towards prevention of human papillomavirus infections and related diseases. Vaccine 2012; 30: F1-11. doi: 10.1016/j.vaccine.2012.05.090
2. Schiller JT, Castellsague X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012; 30: F123-38. doi: 10.1016/j.vaccine.2012.04.108
3. Drolet M, Benard E, Boily M, Ali H, Baandrup L, Bauer H, Beddows S, Brisson J, Brotherton JML, Cummings T, Donovan B, Fairley CK, Flagg EW, Johnson AM, Kahn JA, Kavanagh K, Kjaer SK, Kliewer EV, Lemieux-Melloki P, Markowitz L, Mboup A, Mesher D, Niccolai L. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis 2015. doi: 10.1016/S1473-3099(14) 71073-4
4. Bruni L, Diaz M, Castellsague X, Ferrer E, Bosch FX, De Sanjose S. Cervical human papillomavirus prevalence in 5 continents: metaanalysis of 1 million women with normal cytological findings. J Infect Dis 2010; 202: 1789-99. doi: 10.1086/657321
5. Smith JS, Melendy A, Rana RK, Pimenta JM. Age-specific prevalence of infection with human papillomavirus in females: a global review. J Adolesc Health 2008; 43: S5-25. doi: 10.1016/j.jadohealth.2008.07.009
6. De Sanjose S, Diaz M, Castellsague X, Clifford G, Bruni L, Munoz N, Bosch FX. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 2007; 7: 453-9. doi: 10.1016/S1473-3099(07)70158-5
7. Bosch FX, Burchell AN, Schiffman M, Giuliano AR, De Sanjose S, Bruni L, Tortolero-Luna G, Kjaer SK, Munoz N. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 2008; 26: K1-16. doi: 10.1016/j.vaccine.2008.05.064
8. Franceschi S, Herrero R, Clifford GM, Snijders PJ, Arslan A, Anh PT, Bosch FX, Ferreccio C, Hieu NT, Lazcano-Ponce E, Matos E, Molano M, Qiao Y-L, Rajkuma R, Ronco G, De Sanjose S, Shin H-R, Sukvirach S, Thomas JO, Meijer CJLM, Munoz N. Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. Int J Cancer 2006; 119: 2677-84. doi: 10.1002/ijc.22241
9. Gravitt PE, Rositch AF, Silver MI, Marks MA, Chang K, Burke AE, Viscidi RP. A cohort effect of the sexual revolution may be masking an increase in human papillomavirus detection at menopause in the United States. J Infect Dis 2013; 207: 272-80. doi: 10.1093/infdis/jis660
10. Rositch AF, Burke AE, Viscidi RP, Silver MI, Chang K, Gravitt PE. Contributions of recent and past sexual partnerships on incident human papillomavirus detection: acquisition and reactivation in older women. Cancer Res 2012; 72: 6183-90. doi: 10.1158/0008-5472.CAN-12-2635
11. Gravitt PE. The known unknowns of HPV natural history. J Clin Invest 2011; 121: 4593-9. doi: 10.1172/JCI57149
12. Guan P, Howell-Jones R, Li N, Bruni L, De Sanjose S, Franceschi S, Clifford GM. Human papillomavirus types in 115, 789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer 2012; 131: 2349-59. doi: 10.1002/ijc.27485
13. Garland SM, Brotherton JM, Condon JR, McIntyre PB, Stevens MP, Smith DW, Tabrizi SN. Human papillomavirus prevalence among indigenous and non-indigenous Australian women prior to a national HPV vaccination program. BMC Med 2011; 9: 104. doi: 10.1186/1741-7015-9-104
14. Tabrizi SN, Brotherton JML, Stevens MP, Condon JR, McIntyre PB, Smith D, Garland SM, on behalf of the WHINURS group. HPV genotype prevalence in Australian women undergoing routine cervical screening by cytology status prior to implementation of an HPV vaccination program. J Clin Virol 2014; 60: 250-6. doi: 10.1016/j.jcv.2014.04.013
15. Kjaer SK, Breugelmans G, Munk C, Junge J, Watson M, Iftner T. Population-based prevalence, type-and age-specific distribution of HPV in women before introduction of an HPV-vaccination program in Denmark. Int J Cancer 2008; 123: 1864-70. doi: 10.1002/ijc.23712
16. Kavanagh K, Sinka K, Cuschieri K, Love J, Potts A, Pollock KG, Cubie H, Donaghy M, Robertson C. Estimation of HPV prevalence in young women in Scotland; monitoring of future vaccine impact. BMC Infect Dis 2013; 13: 519. doi: 10.1186/1471-2334-13-519
17. Althoff KN, Paul P, Burke AE, Viscidi R, Sangaramoorthy M, Gravitt PE. Correlates of cervicovaginal human papillomavirus detection in perimenopausal women. J Womens Health 2009; 18: 1341-6. doi: 10.1089/jwh.2008.1223
18. Brogaard KA, Munk C, Iftner T, Frederiksen K, Kjaer SK. Detection of oncogenic genital human papillomavirus (HPV) among HPV negative older and younger women after 7 years of follow-up. J Med Virol 2014; 86: 975-82. doi: 10.1002/jmv.23914
19. Berecki-Gisolf J, Begum N, Dobson AJ. Symptoms reported by women in midlife: menopausal transition or aging?. Menopause 2009; 16: 1021-9. doi: 10.1097/gme.0b013e3181a8c49f
20. Gonzalez P, Hildesheim A, Rodriguez AC, Schiffman M, Porras C, Wacholder S, Pineres AG, Pinto LA, Burk RD, Herrero R. Behavioral/lifestyle and immunologic factors associated with HPV infection among women older than 45 years. Cancer Epidemiol Biomarkers Prev 2010; 19: 3044-54. doi: 10.1158/1055-9965.EPI-10-0645
21. Kjaer SK, Munk C, Junge J, Iftner T. Carcinogenic HPV prevalence and age-specific type distribution in 40, 382 women with normal cervical cytology, ASCUS/LSIL, HSIL, or cervical cancer: what is the potential for prevention?. Cancer Causes Control 2014; 25: 179-89. doi: 10.1007/s10552-013-0320-z